RICHARD ULSTAD: Open Payments
NPI 1356304810 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$600 in 27 payments from 12 companies in 2025. Trend: 2023 $289 · 2024 $1,013 · 2025 $600
Food & beverage: $600
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $172 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| AstraZeneca Pharmaceuticals LP | 3 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| Novo Nordisk Inc | 2 | $40 |
| PFIZER INC. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Exact Sciences Corporation | 1 | $16 |
| TOLMAR, INC. | 1 | $16 |
Products named: Kerendia, JARDIANCE, CAPLYTA, FARXIGA, XIFAXAN, TRINTELLIX, PAXLOVID, Wegovy.
Industry payments across NC — which companies pay providers there.
